Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in duchenne muscular dystrophy

American Journal of Physical Medicine and Rehabilitation

Volumn 88, Issue 6, 2009, Pages 502-522

  Evans, Nicholas P ^a   Misyak, Sarah A ^a   Robertson, John L ^a   Bassaganya Riera, Josep ^b   Grange, Robert W ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

Cytokines; Duchenne muscular dystrophy; Inflammatory gene expression; Intracellular signaling; mdx; Transcription factors

Indexed keywords

CURCUMIN; EPIGALLOCATECHIN GALLATE; ETANERCEPT; GLUCOCORTICOID; GREEN TEA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; DYSTROPHIN;

CROHN DISEASE; DIET SUPPLEMENTATION; DRUG INHIBITION; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; HUMAN; MICROARRAY ANALYSIS; MUSCLE NECROSIS; NONHUMAN; PROTEIN INTERACTION; QUADRICEPS FEMORIS MUSCLE; REVIEW; RHEUMATOID ARTHRITIS; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; MOUSE; MUSCLE CELL; SIGNAL TRANSDUCTION;

ANIMALS; DYSTROPHIN; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MICE; MICE, INBRED MDX; MUSCLE CELLS; MUSCULAR DYSTROPHY, DUCHENNE; SIGNAL TRANSDUCTION;

EID: 66949154340     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHM.0b013e3181a5a24f     Document Type: Review

References (129)

1. Blake DJ, Weir A, Newey SE, et al: Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002;82:291-329 (Pubitemid 34654455)
2. Tidball JG, Wehling-Henricks M: Evolving therapeutic strategies for Duchenne muscular dystrophy: Targeting downstream events. Pediatr Res 2004;56:831-841
3. Straub V, Campbell KP: Muscular dystrophies and the dystrophin- glycoprotein complex. Curr Opin Neurol 1997;10:168-175
4. Durbeej M, Campbell KP: Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev 2002;12:349-361 (Pubitemid 34669835)
5. Oak SA, Zhou YW, Jarrett HW: Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Rac1. J Biol Chem 2003;278:39287-39295
6. Spence HJ, Yun-Ju C, Steven JW: Muscular dystrophies, the cytoskeleton and cell adhesion. Bioessays 2002;24:542-552
7. Bell CD, Conen PE: Histopathological changes in Duchenne muscular dystrophy. J Neurol Sci 1968;7:529-544
8. DiMario JX, Uzman A, Strohman RC: Fiber regeneration is not persistent in dystrophic (mdx) mouse skeletal muscle. Dev Biol 1991;148:314-321 (Pubitemid 121004770)
9. Webster C, Silberstein L, Hays AP, et al: Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988;52:503-513 (Pubitemid 18067515)
10. Collins CA, Morgan JE: Duchenne's muscular dystrophy: Animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003;84:165-172
11. Carpenter S, Karpati G: Pathology of Skeletal Muscle. edition 2. Oxford University Press, 2001, pp 419-435
12. Porter JD, Merriam AP, Khanna S, et al: Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. FASEB J 2003;17:893-895
13. Porter JD, Merriam AP, Leahy P, et al: Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 2003;12:1813-1821 (Pubitemid 36944136)
14. Grady R, Teng H, Nichol MC, et al: Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 1997;90:729-738 (Pubitemid 27357964)
15. Chamberlain JS, Metzger J, Reyes M, et al: Dystrophin- deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007;21:2195-2204 (Pubitemid 47026454)
16. Emery AE: Muscle histology and creatine kinase levels in the foetus in Duchenne muscular dystrophy. Nature 1977;266:472-473 (Pubitemid 8067233)
17. Emery AE, Burt D, Dubowitz V, et al: Antenatal diagnosis of Duchenne muscular dystrophy. Lancet 1979;1:847-849 (Pubitemid 9165941)
18. Mahoney MJ, Haseltine FP, Hobbins JC, et al: Prenatal diagnosis of Duchenne's muscular dystrophy. N Engl J Med 1977;297:968-973 (Pubitemid 8218826)
19. Stengel-Rutkowski L, Scheuerbrandt G, Beckmann R, et al: Prenatal diagnosis of Duchenne's muscular dystrophy. Lancet 1977;1:1359-1360
20. Brooke M, Fenichel G, Griggs R, et al: Clinical investigation in Duchenne dystrophy. 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103
21. Engel AG, Franzinin-Armstrong C: Dystrophinopathies, in Engel AG and Ozawa E (eds): Myology, ed 3. New York, McGraw-Hill, 2004, pp 961-1026
22. Bradley W, Hudgson P, Larson P, et al: Structural changes in the early stages of Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 1972;35:451-455
23. Coulton GR, Morgan JE, Partridge TA, et al: The mdx mouse skeletal muscle myopathy. I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 1988;14:53-70
24. McArdle A, Edwards RHT, Jackson MJ: How does dystrophin deficiency lead to muscle degeneration? Evidence from the MDX mouse. Neuromuscul Disord 1995;5:445-456
25. Carnwath JW, Shotton DM: Muscular dystrophy in the mdx mouse: Histopathology of the soleus and extensor digitorum longus muscles. J Neurosci 1987;80:39-54
26. Hodgetts S, Radley H, Davies M, et al: Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice. Neuromuscul Disord 2006;16:591-602 (Pubitemid 44374323)
27. Pasternak C, Wong S, Elson EL: Mechanical function of dystrophin in muscle cells. J Cell Biol 1995;128:355-361
28. Petrof BJ, Shrager JB, Stedman HH, et al: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993;90:3710-3714 (Pubitemid 23971662)
29. Kumar A, Boriek AM: Mechanical stress activates the nuclear factor-κB pathway in skeletal muscle fibers: A possible role in Duchenne muscular dystrophy. FASEB J 2003;17:386-396 (Pubitemid 36292954)
30. Kumar A, Khandelwal N, Malya R, et al: Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 2004;18:102-113 (Pubitemid 38076470)
31. Porter JD, Guo W, Merriam AP, et al: Persistent over-expression of specific CC class chemokines correlates with macrophage and T cell recruitment in mdx skeletal muscle. Neuromuscul Disord 2003;13:223-235 (Pubitemid 36279427)
32. +) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 2001;98:235-243
33. Wehling M, Spencer MJ, Tidball JG: A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001;155:123-132 (Pubitemid 34286213)
34. Chen YW, Nagaraju K, Bakay M, et al: Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy. Neurology 2005;65:826-834 (Pubitemid 41362124)
35. Pescatori M, Broccolini A, Minetti C, et al: Gene expression profiling in the early phases of DMD: A constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2007;21:1210-1226 (Pubitemid 46495710)
36. Porter JD, Khanna S, Kaminski HJ, et al: A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002;11:263-272 (Pubitemid 34173355)
37. Wolff AV, Niday AK, Voelker KA, et al: Passive mechanical properties of maturing extensor digitorum longus are not affected by lack of dystrophin. Muscle Nerve 2006;34:304-312
38. McArdle A, Edwards R, Jackson M: Time course of changes in plasma membrane permeability in the dystrophin-deficient mdx mouse. Muscle Nerve 1994;17:1378-1384 (Pubitemid 24362809)
39. Allen DG, Whitehead NP, Yeung EW: Mechanisms of stretch-induced muscle damage in normal and dystrophic muscle: Role of ionic changes. J Physiol 2005;567:723-735
40. Kometani K, Tsugeno H, Yamada K: Mechanical and energetic properties of dystrophic (mdx) mouse muscle. Jpn J Physiol 1990;40:541-549
41. Rezvani M, Cafarelli E, Hood DA: Performance and excitability of mdx mouse muscle at 2, 5, and 13 wk of age. J Appl Physiol 1995;78:961-967
42. Grange RW, Gainer TG, Marschner KM, et al: Fasttwitch skeletal muscles of dystrophic mouse pups are resistant to injury from acute mechanical stress. Am J Physiol 2002;283:C1090-C1101
43. Oberc M, Engel W: Ultrastructural localization of calcium in normal and abnormal skeletal muscle. Lab Invest 1977;36:566-577 (Pubitemid 8138833)
44. Yoshida M, Yonetani A, Shirasaki T, et al: Dietary NaCl supplementation prevents muscle necrosis in a mouse model of Duchenne muscular dystrophy. Am J Physiol 2006;290:R449-R455
45. Coulton GR, Curtin NA, Morgan JE, et al: The mdx mouse skeletal muscle myopathy. II. Contractile properties. Neuropathol Appl Neurobiol 1988;14:299-314 (Pubitemid 18193602)
46. Dangain J, Vrbova G: Muscle development in mdx mutant mice. Muscle Nerve 1984;7:700-704 (Pubitemid 15209285)
47. Pastoret C, Sebille A: Time course study of the isometric contractile properties of mdx mouse striated muscles. J Muscle Res Cell Motil 1993;14:423-431 (Pubitemid 23267490)
48. Franco A, Jr, Lansman JB: Calcium entry through stretch-inactivated ion channels in mdx myotubes. Nature 1990;344:670-673 (Pubitemid 20108369)
49. Hutter OF, Burton FL, Bovell DL: Mechanical properties of normal and mdx mouse sarcolemma: Bearing on function of dystrophin. J Muscle Res Cell Motil 1991;12:585-589
50. Bansal D, Miyake K, Vogel SS, et al: Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003;423:168-172 (Pubitemid 36569539)
51. Rando TA: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001;24:1575-1594
52. Vandebrouck A, Sabourin J, Rivet J, et al: Regulation of capacitative calcium entries by α1-syntrophin: Association of TRPC1 with dystrophin complex and the PDZ domain of α1-syntrophin. FASEB J 2007;21:608-617 (Pubitemid 46213507)
53. Fischer GF, Mayr WR: Molecular genetics of the HLA complex. Wien Klin Wochenschr 2001;113:814-824
54. Williams LW, Burks AW, Steele RW: Complement: Function and clinical relevance. Ann Allergy 1988;60:293-300
55. Spuler S, Engel AG: Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 1998;50:41-46 (Pubitemid 28106017)
56. Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9-16
57. Porter JD, Merriam AP, Leahy P, et al: Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum Mol Genet 2004;13:257-269 (Pubitemid 38196166)
58. Zhou L, Porter JD, Cheng G, et al: Temporal and spatial mRNA expression patterns of TGFβ1, 2, 3 and TβRI, II, III in skeletal muscles of mdx mice. Neuromuscul Disord 2006;16:32-38 (Pubitemid 43089624)
59. Gosselin LE, Williams JE, Deering M, et al: Localization and early time course of TGFβ 1 mRNA expression in dystrophic muscle. Muscle Nerve 2004;30:645-653 (Pubitemid 39447289)
60. Van Erp C, Irwin NG, Hoey AJ: Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006;34:327-334 (Pubitemid 44300164)
61. Spencer MJ, Tidball JG: Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord 2001;11:556-564
62. Arahata K, Engel A: Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208 (Pubitemid 14062666)
63. Engel A, Arahata K: Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986;17:704-721 (Pubitemid 16070409)
64. Kuklina EM, Shirshev SV: Role of transcription factor NFAT in the immune response. Biochemistry (Mosc) 2001;66:467-475
65. Macian F, Lopez-Rodriguez C, Rao A: Partners in transcription: NFAT and AP-1. Oncogene 2001;20:2476-2489
66. Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-6866
67. Stupka N, Plant DR, Schertzer JD, et al: Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J Physiol 2006;575:645-656 (Pubitemid 44270187)
68. Ortega-Perez I, Cano E, Were F, et al: c-Jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain. J Biol Chem 2005;280:20867-20878 (Pubitemid 40776792)
69. Olson EN, Williams RS: Calcineurin signaling and muscle remodeling. Cell 2000;101:689-692
70. Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997;15:707-747 (Pubitemid 27169297)
71. Chakkalakal JV, Stocksley MA, Harrison M-A, et al: Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci USA 2003;100:7791-7796
72. Chin ER, Olson EN, Richardson JA, et al: A calcineurin- dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998;12:2499-2509
73. Weir AP, Burton EA, Harrod G, et al: A- and Butrophin have different expression patterns and are differentially up-regulated in mdx muscle. J Biol Chem 2002;277:45285-45290 (Pubitemid 36159134)
74. Weir AP, Morgan JE, Davies KE: A-utrophin upregulation in mdx skeletal muscle is independent of regeneration. Neuromuscul Disord 2004;14:19-23
75. Minetti C, Ricci E, Bonilla E: Progressive depletion of fast α-actinin-positive muscle fibers in Duchenne muscular dystrophy. Neurology 1991;41:1977-1981
76. Stupka N, Gregorevic P, Plant DR, et al: The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol 2004;107:299-310 (Pubitemid 38477356)
77. Chakkalakal JV, Harrison M-A, Carbonetto S, et al: Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum Mol Genet 2004;13:379-388 (Pubitemid 38239789)
78. 2+/calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle. Hum Mol Genet 2006;15:1423-1435
79. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, et al: Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NFAT pathway. FASEB J 2004;18:1937-1939
80. De Luca A, Nico B, Liantonio A, et al: A multidisciplinary evaluation of the effectiveness of cyclosporine A in dystrophic mdx mice. Am J Pathol 2005;166:477-489 (Pubitemid 40189044)
81. Anderson JE, McIntosh LM, Poettcker R: Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 1996;19:1576-1585
82. Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci 2004;117:5965-5973 (Pubitemid 40123963)
83. Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400
84. Davis RJ: Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995;42:459-467
85. Ramji DP, Foka P: CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem J 2002;365:561-575 (Pubitemid 34864439)
86. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000;18:621-663 (Pubitemid 30365393)
87. Karin M, Lin A: NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-227
88. Peter AK, Crosbie RH: Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. Exp Cell Res 2006;312:2580-2591
89. Kristian T, Siesjo BK: Calcium in ischemic cell death. Stroke 1998;29:705-718
90. Monici MC, Aguennouz M, Mazzeo A, et al: Activation of nuclear factor-κB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003;60:993-997 (Pubitemid 36348934)
91. Dudley RW, Khairallah M, Mohammed S, et al: Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am J Physiol 2006;291:R704-R710 (Pubitemid 44352353)
92. Tidball JG, Wehling-Henricks M: The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007;102:1677-1686 (Pubitemid 46571068)
93. i and muscle damage in the mdx mouse. J Physiol 2005;562:367-380
94. Whitehead NP, Yeung EW, Allen DG: Muscle damage in mdx (dystrophic) mice: Role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006;33:657-662
95. Crabtree GR: Calcium, calcineurin, and the control of transcription. J Biol Chem 2001;276:2313-2316
96. Dogra C, Changotra H, Wergedal JE, et al: Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-κB signaling pathways in dystrophin- deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 2006;208:575-585 (Pubitemid 44141882)
97. Messina S, Bitto A, Aguennouz Mh, et al: Nuclear factor-κB blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 2006;198:234-241 (Pubitemid 43243761)
98. Karin M, Gallagher E: From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005;57:283-295 (Pubitemid 40904256)
99. Kolodziejczyk SM, Walsh GS, Balazsi K, et al: Activation of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol 2001;11:1278-1282 (Pubitemid 32774085)
100. Wullaert A, Heyninck K, Beyaert R: Mechanisms of cross-talk between TNF-induced NF-κB and JNK activation in hepatocytes. Biochem Pharmacol 2006;72:1090-1101 (Pubitemid 44465843)
101. Nakamura A, Yoshida K, Ueda H, et al: Up-regulation of mitogen-activated protein kinases in mdx skeletal muscle following chronic treadmill exercise. Biochim Biophys Acta 2005;1740:326-331 (Pubitemid 40804744)
102. Fujioka S, Niu J, Schmidt C, et al: NF-κB and AP-1 connection: Mechanism of NF-κB-dependent regulation of AP-1 activity. Mol Cell Biol 2004;24:7806-7819 (Pubitemid 39121503)
103. Stein B, Baldwin AS Jr, Ballard DW, et al: Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993;12:3879-3891 (Pubitemid 23282764)
104. Reid M, Li Y: Tumor necrosis factor-α and muscle wasting: A cellular perspective. Respir Res 2001;2:269-272 (Pubitemid 34189649)
105. Angelini C: The role of corticosteroids in muscular dystrophy: A critical appraisal. Muscle Nerve 2007;36:424-435 (Pubitemid 47512066)
106. Balaban B, Matthews DJ, Clayton GH, et al: Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil 2005;84:843-850 (Pubitemid 41546724)
107. Connolly AM, Schierbecker J, Renna R, et al: High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917-925 (Pubitemid 35414370)
108. Pradhan S, Ghosh D, Srivastava NK, et al: Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 2006;253:1309-1316 (Pubitemid 44691555)
109. Keeling RM, Golumbek PT, Streif EM, et al: Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 2007;35:43-48
110. Merlini L, Cicognani A, Malaspina E, et al: Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003;27:222-227 (Pubitemid 36169334)
111. De Bosscher K, Van Craenenbroeck K, Meijer OC, et al: Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol 2008;583:290-302
112. Barnes PJ: Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci (Lond) 1998;94:557-572 (Pubitemid 28269054)
113. Auphan N, DiDonato JA, Rosette C, et al: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-290
114. Karin M, Chang L: AP-1-glucocorticoid receptor cross-talk taken to a higher level. J Endocrinol 2001;169:447-451 (Pubitemid 32536977)
115. Acharyya S, Villalta S, Bakkar N, et al: Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007;117:889-901 (Pubitemid 46556745)
116. Marx J: How the glucocorticoids suppress immunity. Science 1995;270:232-233
117. Wisniewska M, Stanczyk M, Grzelakowska-Sztabert B, et al: Nuclear factor of activated T cells (NFAT) is a possible target for dexamethasone in thymocyte apoptosis. Cell Biol Int 1997;21:127-132 (Pubitemid 27202295)
118. Wisniewska M, Pyrzynska B, Kaminska B: Impaired AP-1 dimers and NFAT complex formation in immature thymocytes during in vivo glucocorticoid-induced apoptosis. Cell Biol Int 2004;28:773-780 (Pubitemid 39550358)
119. Vacca A, Felli MP, Farina AR, et al: Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992;175:637-646
120. Radley HG, De Luca A, Lynch GS, et al: Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol 2007;39:469-477 (Pubitemid 46096791)
121. Grounds MD, Torrisi JO: Anti-TNFα (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004;18:676-682
122. Dorchies OM, Wagner S, Vuadens O, et al: Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol 2006;290:C616-C625
123. Qin J, Xie LP, Zheng XY, et al: A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun 2007;354:852-857 (Pubitemid 46216211)
124. Sah JF, Balasubramanian S, Eckert RL, et al: Epigallocatechin- 3-gallate inhibits epidermal growth factor receptor signaling pathway: Evidence for direct inhibition of ERK1/2 and Akt kinases. J Biol Chem 2004;279:12755-12762 (Pubitemid 38445847)
125. Chen PC, Wheeler DS, Malhotra V, et al: A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IκB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 2002;26:233-241 (Pubitemid 34971887)
126. Yang F, Oz HS, Barve S, et al: The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-κB activation by inhibiting IκB kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001;60:528-533 (Pubitemid 32781560)
127. Durham WJ, Arbogast S, Gerken E, et al: Progressive nuclear factor-κB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 2006;34:298-303 (Pubitemid 44300160)
128. + occlusion, and inhibition of hydrolytic activity. Br J Pharmacol 2005;145:236-245
129. Pan Y, Chen C, Shen Y, et al: Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol Cells 2008;25:531-537